500 related articles for article (PubMed ID: 33042828)
1. Transcriptome-Based Network Analysis Unveils Eight Immune-Related Genes as Molecular Signatures in the Immunomodulatory Subtype of Triple-Negative Breast Cancer.
Zhang J; Wang L; Xu X; Li X; Guan W; Meng T; Xu G
Front Oncol; 2020; 10():1787. PubMed ID: 33042828
[No Abstract] [Full Text] [Related]
2. Novel biomarkers identified in triple-negative breast cancer through RNA-sequencing.
Chen YL; Wang K; Xie F; Zhuo ZL; Liu C; Yang Y; Wang S; Zhao XT
Clin Chim Acta; 2022 Jun; 531():302-308. PubMed ID: 35504321
[TBL] [Abstract][Full Text] [Related]
3. Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer.
Chen X; Li Z; Liang M; Zhang Z; Zhu D; Lin B; Zhou R; Lu Y
World J Surg Oncol; 2023 Jun; 21(1):194. PubMed ID: 37391802
[TBL] [Abstract][Full Text] [Related]
4. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.
Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
Front Immunol; 2021; 12():749459. PubMed ID: 34603338
[TBL] [Abstract][Full Text] [Related]
5. Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis.
Zhai Q; Li H; Sun L; Yuan Y; Wang X
Breast Cancer; 2019 Nov; 26(6):784-791. PubMed ID: 31197620
[TBL] [Abstract][Full Text] [Related]
6. A novel fatty-acid metabolism-based classification for triple negative breast cancer.
Yang X; Tang W; He Y; An H; Wang J
Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837
[TBL] [Abstract][Full Text] [Related]
7. Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature.
Zhang S; Lv M; Cheng Y; Wang S; Li C; Qu X
BMC Cancer; 2021 Dec; 21(1):1324. PubMed ID: 34893046
[TBL] [Abstract][Full Text] [Related]
8. Establishment and validation of an individualized macrophage-related gene signature to predict overall survival in patients with triple negative breast cancer.
Su P; Peng Z; Xu B; Yang B; Jin F
PeerJ; 2021; 9():e12383. PubMed ID: 34900411
[TBL] [Abstract][Full Text] [Related]
9. Research and experimental verification on the mechanisms of cellular senescence in triple-negative breast cancer.
Cao T; Huang M; Huang X; Tang T
PeerJ; 2024; 12():e16935. PubMed ID: 38435998
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
[TBL] [Abstract][Full Text] [Related]
11. Identification of CTLA-4 associated with tumor microenvironment and competing interactions in triple negative breast cancer by co-expression network analysis.
Peng Z; Su P; Yang Y; Yao X; Zhang Y; Jin F; Yang B
J Cancer; 2020; 11(21):6365-6375. PubMed ID: 33033520
[No Abstract] [Full Text] [Related]
12. Identification of immunosuppressive signature subtypes and prognostic risk signatures in triple-negative breast cancer.
Ding R; Wang Y; Fan J; Tian Z; Wang S; Qin X; Su W; Wang Y
Front Oncol; 2023; 13():1108472. PubMed ID: 37377907
[TBL] [Abstract][Full Text] [Related]
13. Identification of new subtypes and potential genetic signatures in triple-negative breast cancer using weighted gene co-expression network analysis.
Huang J; Liao LY; Jiang WJ; Li YH; Lu BM; Wen ZP; Li FJ; Fang DL; Lu GM
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):603-614. PubMed ID: 38305604
[TBL] [Abstract][Full Text] [Related]
14. The Expression and Prognostic Value of SUMO1-Activating Enzyme Subunit 1 and Its Potential Mechanism in Triple-Negative Breast Cancer.
Wang Q; Zhong W; Deng L; Lin Q; Lin Y; Liu H; Xu L; Lu L; Chen Y; Huang J; Jiang M; Xiao H; Zhang J; Li H; Lin Y; Song C; Lin Y
Front Cell Dev Biol; 2021; 9():729211. PubMed ID: 34621746
[No Abstract] [Full Text] [Related]
15. A novel immune checkpoint-related gene signature for predicting overall survival and immune status in triple-negative breast cancer.
Liu J; Ling Y; Su N; Li Y; Tian S; Hou B; Luo S; Zhao L; Shi M
Transl Cancer Res; 2022 Jan; 11(1):181-192. PubMed ID: 35261895
[TBL] [Abstract][Full Text] [Related]
16. Identification of hub genes and diagnostic efficacy for triple-negative breast cancer through WGCNA and Mendelian randomization.
Lin Y; Wang S; Yang Q
Discov Oncol; 2024 Apr; 15(1):117. PubMed ID: 38609711
[TBL] [Abstract][Full Text] [Related]
17. Identification of
Wang F; Cao X; Yin L; Wang Q; He Z
DNA Cell Biol; 2020 Oct; 39(10):1813-1824. PubMed ID: 32816580
[TBL] [Abstract][Full Text] [Related]
18. Retrospective study of transcriptomic profiling identifies Thai triple-negative breast cancer patients who may benefit from immune checkpoint and PARP inhibitors.
Suntiparpluacha M; Chanthercrob J; Sa-Nguanraksa D; Sitthikornpaiboon J; Chaiboonchoe A; Kueanjinda P; Jinawath N; Sampattavanich S
PeerJ; 2023; 11():e15350. PubMed ID: 37334114
[TBL] [Abstract][Full Text] [Related]
19. Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy.
Zhou Y; Che Y; Fu Z; Zhang H; Wu H
Front Public Health; 2022; 10():902378. PubMed ID: 35875026
[TBL] [Abstract][Full Text] [Related]
20. Identification of CXCR4 and CXCL10 as Potential Predictive Biomarkers in Triple Negative Breast Cancer (TNBC).
Chuan T; Li T; Yi C
Med Sci Monit; 2020 Jan; 26():e918281. PubMed ID: 31924747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
